keyword
MENU ▼
Read by QxMD icon Read
search

Alzheimers monitoring

keyword
https://www.readbyqxmd.com/read/28101398/wide-field-retinal-optical-coherence-tomography-with-wavefront-sensorless-adaptive-optics-for-enhanced-imaging-of-targeted-regions
#1
James Polans, Brenton Keller, Oscar M Carrasco-Zevallos, Francesco LaRocca, Elijah Cole, Heather E Whitson, Eleonora M Lad, Sina Farsiu, Joseph A Izatt
The peripheral retina of the human eye offers a unique opportunity for assessment and monitoring of ocular diseases. We have developed a novel wide-field (>70°) optical coherence tomography system (WF-OCT) equipped with wavefront sensorless adaptive optics (WSAO) for enhancing the visualization of smaller (<25°) targeted regions in the peripheral retina. We iterated the WSAO algorithm at the speed of individual OCT B-scans (~20 ms) by using raw spectral interferograms to calculate the optimization metric...
January 1, 2017: Biomedical Optics Express
https://www.readbyqxmd.com/read/28097868/development-of-phenothiazine-based-theranostic-compounds-that-act-both-as-inhibitors-of-%C3%AF-amyloid-aggregation-and-imaging-probes-for-amyloid-plaques-in-alzheimer-s-disease
#2
Pascal Dao, Feifei Ye, Yan Liu, Zhiyun Du, Kun Zhang, Chang-Zhi Dong, Bernard Meunier, Huixiong Chen
Early detection of Alzheimer's disease (AD) is imperative in enabling the understanding and clinical treatment of this disorder, as well as in preventing its progression. Imaging agents specifically targeting Aβ plaques in the brain and the retina may lead to the early diagnosis of AD. Among them, near infrared fluorescent imaging has emerged as an attractive tool to noninvasively identify and monitor diseases during the preclinical and early stages. In the present study, we report the design, synthesis and evaluation of a series of new near-infrared fluorescent probes...
January 18, 2017: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/28088881/an-industry-update-the-latest-developments-in-therapeutic-delivery
#3
Iain Simpson
This Industry Update covers the period from 1 October through to 31 October 2016, and is based on information sourced from company press releases, scientific literature, patents and various news websites. The month saw several news items covering drug-delivery devices, including a new sensor to monitor and support the use of inhalers; launch in the UK of a new autoinjector for Cimzia(®), UCB's rheumatoid arthritis drug; and approval of Roche's Lucentis(®) in a prefilled syringe. Research was also published to show the value of continuous blood pressure monitoring in dementia management...
February 2017: Therapeutic Delivery
https://www.readbyqxmd.com/read/28073262/fluorescence-self-quenching-from-reporter-dyes-informs-on-the-structural-properties-of-amyloid-clusters-formed-in-vitro-and-in-cells
#4
WeiYue Chen, Laurence J Young, Meng Lu, Alessio Zaccone, Florian Ströhl, Na Yu, Gabriele S Kaminski Schierle, Clemens F Kaminski
The characterization of the aggregation kinetics of protein amyloids and the structural properties of the ensuing aggregates are vital in the study of the pathogenesis of many neurodegenerative diseases and the discovery of therapeutic targets. In this article, we show that the fluorescence lifetime of synthetic dyes covalently attached to amyloid proteins informs on the structural properties of amyloid clusters formed both in vitro and in cells. We demonstrate that the mechanism behind such a "lifetime sensor" of protein aggregation is based on fluorescence self-quenching and that it offers a good dynamic range to report on various stages of aggregation without significantly perturbing the process under investigation...
January 11, 2017: Nano Letters
https://www.readbyqxmd.com/read/28066979/when-proteostasis-goes-bad-protein-aggregation-in-the-cell
#5
REVIEW
Mona Radwan, Rebecca J Wood, Xiaojing Sui, Danny M Hatters
Protein aggregation is a hallmark of the major neurodegenerative diseases including Alzheimer's, Parkinson's, Huntington's and motor neuron and is a symptom of a breakdown in the management of proteome foldedness. Indeed, it is remarkable that under normal conditions cells can keep their proteome in a highly crowded and confined space without uncontrollable aggregation. Proteins pose a particular challenge relative to other classes of biomolecules because upon synthesis they must typically follow a complex folding pathway to reach their functional conformation (native state)...
January 9, 2017: IUBMB Life
https://www.readbyqxmd.com/read/28059789/the-mild-behavioral-impairment-checklist%C3%A2-mbi-c-a-rating-scale-for%C3%A2-neuropsychiatric-symptoms-in%C3%A2-pre-dementia-populations
#6
Zahinoor Ismail, Luis Agüera-Ortiz, Henry Brodaty, Alicja Cieslak, Jeffrey Cummings, Corinne E Fischer, Serge Gauthier, Yonas E Geda, Nathan Herrmann, Jamila Kanji, Krista L Lanctôt, David S Miller, Moyra E Mortby, Chiadi U Onyike, Paul B Rosenberg, Eric E Smith, Gwenn S Smith, David L Sultzer, Constantine Lyketsos
BACKGROUND: Mild behavioral impairment (MBI) is a construct that describes the emergence at ≥50 years of age of sustained and impactful neuropsychiatric symptoms (NPS), as a precursor to cognitive decline and dementia. MBI describes NPS of any severity, which are not captured by traditional psychiatric nosology, persist for at least 6 months, and occur in advance of or in concert with mild cognitive impairment. While the detection and description of MBI has been operationalized in the International Society to Advance Alzheimer's Research and Treatment - Alzheimer's Association (ISTAART-AA) research diagnostic criteria, there is no instrument that accurately reflects MBI as described...
December 3, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28058286/close-correlation-of-monoamine-oxidase-activity-with-progress-of-alzheimer-s-disease-in-mice-observed-by-in-vivo-two-photon-imaging
#7
Dokyoung Kim, Sung Hoon Baik, Seokjo Kang, Seo Won Cho, Juryang Bae, Moon-Yong Cha, Michael J Sailor, Inhee Mook-Jung, Kyo Han Ahn
Monoamine oxidases (MAOs) play an important role in Alzheimer's disease (AD) pathology. We report in vivo comonitoring of MAO activity and amyloid-β (Aβ) plaques dependent on the aging of live mice with AD, using a two-photon fluorescence probe. The probe under the catalytic action of MAO produces a dipolar fluorophore that senses Aβ plaques, a general AD biomarker, enabling us to comonitor the enzyme activity and the progress of AD indicated by Aβ plaques. The results show that the progress of AD has a close correlation with MAO activity, which can be categorized into three stages: slow initiation stage up to three months, an aggressive stage, and a saturation stage from nine months...
December 28, 2016: ACS Central Science
https://www.readbyqxmd.com/read/28039808/analysis-of-amino-acid-and-monoamine-neurotransmitters-and-their-metabolites-in-rat-urine-of-alzheimer-s-disease-using-in-situ-ultrasound-assisted-derivatization-dispersive-liquid-liquid-microextraction-with-uhplc-ms-ms
#8
Xian-En Zhao, Yongrui He, Meng Li, Guang Chen, Na Wei, Xiao Wang, Jing Sun, Shuyun Zhu, Jinmao You
Neurotransmitters (NTs) may play an important role in neurodegenerative disorders such as Alzheimer's disease (AD). In order to investigate the potential links, a new simple, fast, accurate and sensitive analytical method, based on in situ ultrasound-assisted derivatization dispersive liquid-liquid microextraction (in situ UA-DDLLME) coupled with ultra high-performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), has been developed and validated. The quantitation of amino acid neurotransmitters (AANTs) and monoamine neurotransmitters (MANTs) in urine of AD rats were performed in this work...
December 26, 2016: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/28030361/redox-sensitive-gfp-to-monitor-oxidative-stress-in-neurodegenerative-diseases
#9
Sonia Esposito, Alessandra Masala, Simona Sanna, Mauro Rassu, Viengsavanh Pimxayvong, Ciro Iaccarino, Claudia Crosio
Redox processes are key events in the degenerative cascade of many adult-onset neurodegenerative diseases (NDs), but the biological relevance of a single redox change is often dependent on the redox couple involved and on its subcellular origin. The biosensors based on engineered fluorescent proteins (redox-sensitive GFP [roGFP]) offer a unique opportunity to monitor redox changes in both physiological and pathological contexts in living animals and plants. Here, we review the use of roGFPs to monitor oxidative stress in different three adult-onset NDs: Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)...
December 28, 2016: Reviews in the Neurosciences
https://www.readbyqxmd.com/read/28011193/monitoring-ca-2-elevations-in-individual-astrocytes-upon-local-release-of-amyloid-beta-in-acute-brain-slices
#10
Olga Tyurikova, Kaiyu Zheng, Annika Rings, Anna Drews, David Klenerman, Dmitri A Rusakov
The pathogenesis of Alzheimer's disease (AD) is thought to involve acute neurotoxic effects exerted by oligomeric forms of amyloid-β 1-42 (Aβ). Application of Aβ oligomers in physiological concentrations have been shown to transiently elevate internal Ca(2+) in cultured astroglia. While the cellular machinery involved has been extensively explored, to what degree this important signalling cascade occurs in organised brain tissue has remained unclear. Here we adapted two-photon excitation microscopy and calibrated time-resolved imaging (FLIM), coupled with patch-clamp electrophysiology, to monitor Ca(2+) concentration ([Ca(2+)]) inside individual astrocytes and principal neurons in acute brain slices...
December 20, 2016: Brain Research Bulletin
https://www.readbyqxmd.com/read/28004155/-retinal-imaging-of-the-macula-and-optic-disc-in-neurodegenerative-diseases
#11
G N Turski, S Schmitz-Valckenberg, F G Holz, R P Finger
BACKGROUND: Due to current demographic trends, the prevalence of mild cognitive impairment and dementia is expected to increase considerably. For potential new therapies it is important to identify patients at risk as early as possible. Currently, there is no population-based screening. Therefore, identification of biomarkers that will help screen the population at risk is urgently needed. Thus, a literature review on retinal pathology in neurodegenerative diseases was performed. METHODS: PubMed was searched for studies published up to August 2016 using the following keywords: "mild cognitive impairment", "dementia", "eye", "ocular biomarkers", "OCT" and "OCT angiography"...
December 21, 2016: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
https://www.readbyqxmd.com/read/28000893/hyperlipidemia-induced-apoptosis-of-hippocampal-neurons-in-apoe-mice-may-be-associated-with-increased-pcsk9-expression
#12
Xue-Shan Zhao, Qi Wu, Juan Peng, Li-Hong Pan, Zhong Ren, Hui-Ting Liu, Zhi-Sheng Jiang, Gui-Xue Wang, Zhi-Han Tang, Lu-Shan Liu
Hyperlipidemia is a risk factor for Alzheimer's disease (AD) and other neurodegenerative diseases. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a lipid regulatory gene involved in cell apoptosis. However, the function and mechanism of PCSK9 in neuronal apoptosis following hyperlipidemia remains to be elucidated. The present study established a hyperlipidemic mouse model by feeding a high‑fat diet (HFD) to 6‑week‑old apoE(‑/‑) mice. Plasma lipid levels, hippocampal lipid accumulation, hippocampal histology, and hippocampal neuronal apoptosis were all monitored for changes...
February 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/27992175/label-free-electrochemical-biosensor-for-monitoring-of-chloride-ion-in-an-animal-model-of-alzhemier-s-disease
#13
Hui Dong, Limin Zhang, Wei Liu, Yang Tian
The potential damage of Alzheimer's disease (AD) in brain function has attracted extensive attention. As the most common anion, Cl(-) has been indicated to play significant roles in brain diseases, particularly in the pathological process of AD. In this work, a label-free selective and accurate electrochemical biosensor was first developed for real-time monitoring of Cl(-) levels in a mouse brain model of AD and rat brain upon global cerebral ischemia. Silver nanoparticles (AgNPs) were designed and synthesized as selective recognition element for Cl(-), while 5'-MB-GGCGCGATTTT-SH-3' (SH-DNA-MB, MB = methylene blue) was selected as an inner reference molecule for a built-in correction to avoid the effects from the complicated brain...
December 19, 2016: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/27983548/deep-brain-stimulation-for-alzheimer-s-disease-ethical-challenges-for-clinical-research
#14
Andrew M Siegel, Marna S Barrett, Mahendra T Bhati
Deep brain stimulation (DBS) is an invasive neuromodulation modality that has shown early promise as a novel treatment of Alzheimer's disease (AD). Further clinical research is warranted on the basis of positive results from animal and human studies, as well as the inadequacy of existing treatments in reducing the enormous medical and financial costs of untreated AD. Nevertheless, unique ethical challenges require particular attention to elements of subject enrollment and informed consent. Study protocols should specify robust assessment and regular monitoring of subject decision-making capacity to consent to trial participation...
December 9, 2016: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/27978792/predicting-stability-of-mild-cognitive-impairment-mci-findings-of-a-community-based-sample
#15
Sinika Ellendt, Bianca Voß, Nils Kohn, Lisa Wagels, Katharina Goerlich, Eva Drexler, Frank Schneider, Ute Habel
BACKGROUND: Mild Cognitive Impairment (MCI) is a risk factor for Alzheimer's disease (AD) and other forms of dementia. However, much heterogeneity concerning neuropsychological measures, prevalence and progression rates impedes distinct diagnosis and treatment implications. OBJECTIVE: Aim of the present study was the identification of specific tests providing a high certainty for stable MCI and factors that precipitate instability of MCI in a community based sample examined at three measurement points...
December 13, 2016: Current Alzheimer Research
https://www.readbyqxmd.com/read/27964994/magnetic-resonance-spectroscopy-and-brain-volumetry-in-mild-cognitive-impairment-a-prospective-study
#16
Nicolás Fayed, Pedro J Modrego, Gracián García-Martí, Roberto Sanz-Requena, Luis Marti-Bonmatí
OBJECTIVE: To assess the accuracy of magnetic resonance spectroscopy (1H-MRS) and brain volumetry in mild cognitive impairment (MCI) to predict conversion to probable Alzheimer's disease (AD). METHODS: Forty-eight patients fulfilling the criteria of amnestic MCI who underwent a conventional magnetic resonance imaging (MRI) followed by MRS, and T1-3D on 1.5 Tesla MR unit. At baseline the patients underwent neuropsychological examination. 1H-MRS of the brain was carried out by exploring the left medial occipital lobe and ventral posterior cingulated cortex (vPCC) using the LCModel software...
December 11, 2016: Magnetic Resonance Imaging
https://www.readbyqxmd.com/read/27941122/first-pet-imaging-studies-with-63zn-zinc-citrate-in-healthy-human-participants-and-patients-with-alzheimer-disease
#17
Timothy R DeGrado, Bradley J Kemp, Mukesh K Pandey, Huailei Jiang, Tina M Gunderson, Logan R Linscheid, Allison R Woodwick, Daniel M McConnell, Joel G Fletcher, Geoffrey B Johnson, Ronald C Petersen, David S Knopman, Val J Lowe
Abnormalities in zinc homeostasis are indicated in many human diseases, including Alzheimer disease (AD). (63)Zn-zinc citrate was developed as a positron emission tomography (PET) imaging probe of zinc transport and used in a first-in-human study in 6 healthy elderly individuals and 6 patients with clinically confirmed AD. Dynamic PET imaging of the brain was performed for 30 minutes following intravenous administration of (63)Zn-zinc citrate (∼330 MBq). Subsequently, body PET images were acquired. Urine and venous blood were analyzed to give information on urinary excretion and pharmacokinetics...
2016: Molecular Imaging
https://www.readbyqxmd.com/read/27931796/the-alzheimer-s-disease-neuroimaging-initiative-3-continued-innovation-for-clinical-trial-improvement
#18
REVIEW
Michael W Weiner, Dallas P Veitch, Paul S Aisen, Laurel A Beckett, Nigel J Cairns, Robert C Green, Danielle Harvey, Clifford R Jack, William Jagust, John C Morris, Ronald C Petersen, Jennifer Salazar, Andrew J Saykin, Leslie M Shaw, Arthur W Toga, John Q Trojanowski
INTRODUCTION: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study. METHODS: ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis...
December 5, 2016: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://www.readbyqxmd.com/read/27928377/macular-thickness-in-subjective-memory-complaints-and-mild-cognitive-impairment-a-non-invasive-biomarker
#19
Domingo Giménez Castejón, Miriama Dudekova, Maria Gómez Gallego, Jerónimo Lajara Blesa
Alzheimer's disease (AD) is the main cause of dementia worldwide, which implies an important socioeconomic problem in developed countries. Efforts to find biomarkers to diagnose AD have been intensified, especially, to detect cognitive impairment in its early stages, also known as mild cognitive impairment (MCI). Besides, there are individuals referring memory loss that is unnoticeable in the family environment and presenting normal neuropsychological tests. The former patients are included in a clinical picture that has been recently called subjective memory complaints (SMC)...
February 2016: Neuro-ophthalmology
https://www.readbyqxmd.com/read/27927987/ion-channel-formation-by-amyloid-%C3%AE-42-oligomers-but-not-amyloid-%C3%AE-40-in-cellular-membranes
#20
David C Bode, Mark D Baker, John H Viles
A central hallmark of Alzheimer's disease (AD) is the presence of extracellular amyloid plaques chiefly consisting of amyloid-β (Aβ) peptides in the brain interstitium. Aβ largely exists in two isoforms, 40 or 42 amino acids long, while a large body of evidence points to Aβ(1-42) rather than Aβ(1-40) as the cytotoxic form. One proposed mechanism by which Aβ exerts toxicity is the formation of ion channel pores that disrupt intracellular Ca(2+) homeostasis. However, previous studies using membrane mimetics have not identified any notable difference in the channel-forming properties between Aβ(1-40) and Aβ(1-42)...
December 7, 2016: Journal of Biological Chemistry
keyword
keyword
21037
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"